HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Crouch, Z. Articles by DeSantis, E. R. H. Search for Related Content PubMed PubMed Citation Articles by Crouch, Z. Articles by DeSantis, E. R. H.

ZACHARY CROUCH is Pharm.D. candidate, Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, Piscataway. EVELYN R. HERMES DESANTIS, PHARMD., BCPS, is Director, Drug Information Service, Robert Wood Johnson University Hospital, New Brunswick, NJ, and Clinical Associate Professor, Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey.

Address correspondence to Dr. Hermes DeSantis at the Ernest Mario School of Pharmacy, Pharmacy Practice, Rutgers, The State University of New Jersey, 160 Frelinghuysen Road, Piscataway, NJ 08854 (ehermesd{at}rci.rutgers.edu).

Purpose. The treatment of cancer-induced anemia with erythropoietin-stimulating agents (ESAs) is reviewed. Summary. Before the introduction of ESAs, the only treatment option for cancer-related anemia was red blood cell (RBC) transfusion. The use of ESAs in multiple disease states has been well established and is now considered first-line treatment for many forms of anemia. Chang et al. evaluated the effect of epoetin alfa (40,000 units administered subcutaneously every week) and standard-of-care therapy on quality of life (QOL), transfusion requirements, and hemoglobin levels in 354 patients with breast cancer who had a baseline hemoglobin concentration of <15 g/dL. The authors concluded that early initiation of treatment with epoetin alfa in patients with breast cancer is effective in maintaining hemoglobin levels, reducing transfusions, and improving QOL. Leyland-Jones et al. conducted a study evaluating the effects of early intervention with epoetin alfa (40,000 units administered subcutaneously every week) on survival and QOL of mainly nonanemic patients with metastatic breast cancer. In contrast to Chang et al., this study was discontinued because of lower overall survival rates within the epoetin alfa group. In 2008, the Food and Drug Administration issued a black-box warning for both epoetin alfa and darbepoetin alfa. The warning acknowledges that ESAs have shortened overall survival and time to disease progression in patients with advanced breast cancer who are given these agents to achieve a target hemoglobin concentration of 12 g/dL. Conclusion. When used in patients with cancer-induced anemia, ESAs should only be given at the lowest dose possible to prevent RBC transfusions. During treatment, hemoglobin levels should be monitored closely and ESA doses need to be adjusted accordingly. Index terms: Anemia; Breast neoplasms; Darbepoetin alfa; Dosage; Epoetin alfa; Hematopoietic agents; Quality of life; Toxicity